Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting
Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting
Acumen Pharmaceuticals 在美國神經病學會 2024 年年會上公佈了 Sabirnetug 的首份綜合臨床和生物標誌物數據
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changes
Presentation to be featured during AAN Emerging Science Session
Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024
演示和海報包括有關sabirnetug安全概況、目標參與和流體生物標誌物變化的更深入的數據見解
演講將在 AAN 新興科學會議期間展出
公司有望在2024年上半年啓動評估sabirnetug的第二階段試驗
CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session...
弗吉尼亞州夏洛茨維爾，2024年4月16日（GLOBE NEWSWIRE）——Acumen Pharmicals, Inc...
登入免費觀看全文
登入/註冊